NDA 022030 · Pfizer
Toviaz
Fesoterodine Fumarate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Oct 31, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
59
16 Phase 3, 0 recruiting
FAERS reports
10,803
6,068 serious, 439 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2026.
Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Toviaz is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Toviaz is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.
Mechanism: Fesoterodine is a competitive muscarinic receptor antagonist. After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine. Muscarinic receptors play a role in contractions of urinary bladder smooth muscle. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine produces its effects.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 17, 2021 Supplement 19 · Efficacy · priority review LetterLabel
- Oct 31, 2008 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewLabel
2 products under this application
- TOVIAZ · FESOTERODINE FUMARATE 4MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- TOVIAZ · FESOTERODINE FUMARATE 8MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fesoterodine" as an intervention, any sponsor and status, largest first.
- Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00611026 · 2,417 participants · Start Feb 2008 · Primary completion Oct 2009
Drug: Tolterodine ER; Placebo and 1 more · For: Overactive Bladder
Sites: Enterprise, Alabama; Mobile, Alabama; Montgomery, Alabama · 227 sites in all
- A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of FesoterodinePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01302067 · 2,012 participants · Start May 2011 · Primary completion Nov 2012
Drug: Fesoterodine 8mg; Fesoterodine 4mg and 1 more · For: Overactive Bladder
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 293 sites in all
- Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00444925 · 1,712 participants · Start Apr 2007 · Primary completion Jul 2008
Drug: fesoterodine fumarate; placebo and 1 more · For: Overactive Bladder
Sites: Homewood, Alabama; Huntsville, Alabama; Mobile, Alabama · 178 sites in all
- A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01302054 · 990 participants · Start May 2011 · Primary completion May 2012
Drug: Fesoterodine 8 mg; Placebo · For: Urinary Bladder, Overactive
Sites: Birmingham, Alabama; Fairhope, Alabama; Chandler, Arizona · 176 sites in all
- A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary UrgencyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00911937 · 963 participants · Start Aug 2009 · Primary completion Sep 2011
Drug: Fesoterodine; Placebo · For: Overactive Bladder
Sites: Mobile, Alabama; Goodyear, Arizona; Litchfield Park, Arizona · 112 sites in all
- Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00561951 · 951 participants · Start Nov 2007 · Primary completion Jan 2009
Drug: fesoterodine fumarate; Placebo and 1 more · For: Overactive Bladder
Sites: Kowloon, Hong Kong; Shatin, Hong Kong; Nagoya, Japan · 65 sites in all
- Fesoterodine "add-on" Male Overactive Bladder StudyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00546637 · 947 participants · Start Nov 2007 · Primary completion Feb 2009
Drug: Fesoterodine; Placebo · For: Overactive Bladder Syndrome
Sites: Birmingham, Alabama; Gilbert, Arizona; Litchfield Park, Arizona · 137 sites in all
- Fesoterodine Flexible Dose StudyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00536484 · 896 participants · Start Aug 2007 · Primary completion Mar 2008
Drug: Fesoterodine; Placebo · For: Overactive Bladder
Sites: Mobile, Alabama; Chandler, Arizona; Peoria, Arizona · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,689
- dry mouth823
- fall535
- off label use531
- fatigue527
- constipation508
- urinary retention502
- pain466
- headache435
- dizziness397
- condition aggravated349
- confusional state348
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 80 |
| 2010 | 1,035 |
| 2011 | 544 |
| 2012 | 904 |
| 2013 | 1,023 |
| 2014 | 813 |
| 2015 | 618 |
| 2016 | 704 |
| 2017 | 601 |
| 2018 | 677 |
| 2019 | 825 |
| 2020 | 882 |
| 2021 | 619 |
| 2022 | 516 |
| 2023 | 358 |
| 2024 | 265 |
| 2025 | 225 |
| 2026 | 112 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Toviaz (Fesoterodine Fumarate)
2024 spending
$2.6M
Beneficiaries
1,675
6,052 claims
Per beneficiary
$1,574
$8.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $180,987,271 |
| 2021 | $162,783,116 |
| 2022 | $107,715,372 |
| 2023 | $8,530,726 |
| 2024 | $2,636,887 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, et al. · Int Braz J Urol 2023 · Systematic Review, Network Meta-Analysis
- Fesoterodine: Pharmacological properties and clinical implications.
Gamé X, Peyronnet B, Cornu JN · Eur J Pharmacol 2018 · Systematic Review
- On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics.
Bozkurt IH, Sefik E, Celik S, et al. · Int Urogynecol J 2022 · Randomized Controlled Trial
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Pharmacokinetic profile of fesoterodine.
Malhotra B, Guan Z, Wood N, et al. · Int J Clin Pharmacol Ther 2008 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- [The efficacy of fesoterodine in patients after transurethral resection of the prostate].
Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA · Urologiia 2019 · Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.